Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Diabetes Obes MetabJul 6, 2026 (epub)
A B M Kamrul-Hasan, Subhankar Chatterjee, Hamid Ashraf et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy and safety of mazdutide in 2292 predominantly Chinese adults with obesity and/or type 2 diabetes. The study found that mazdutide significantly reduced body weight and HbA1c levels compared to placebo, with reductions of -6.56%, -9.92%, and -11.1% for different doses in non-diabetic individuals, and also outperformed dulaglutide in diabetic patients.
Key findings
- Mazdutide 3, 4, and 6 mg reduced body weight by -6.56%, -9.92%, and -11.1% compared to placebo.
- In type 2 diabetes, mazdutide 4 and 6 mg reduced HbA1c levels compared to placebo.
- Mazdutide improved waist circumference, lipids, liver enzymes, and uric acid levels.
- Gastrointestinal adverse events were more frequent, but serious adverse events were comparable to comparators.
Why it matters
The findings suggest that mazdutide may offer significant weight loss and metabolic improvements for patients with obesity and type 2 diabetes, which are critical factors in managing these conditions effectively.